.
   
  Home  |  About Journal  |  Browse Articles  |  Editorial Board  |  Authors Guidelines  |  Submit Article  |  FAQ  |  Contact  
   

IJCRIMPH Articles:

Safety and efficacy of rennin-angiotensin system inhibitors in heart failure with preserved ejection fraction IJCRIMPH articles are provided for free based on an Open Access policy
'
International Journal of Collaborative Research on Internal Medicine & Public Health, 2011 - Vol. 3 No. 4

Author(s): Mukesh Singh, Tejaskumar Shah, Sasikanth Adigopula, Sandeep Khosla, Rohit Arora, Evyan Jawad

Department of Cardiology, Chicago Medical School, United States



Abstract:
-----------------------------
Background: Approximately half of the patients with chronic heart failure have preserved left ventricular systolic function. The trials of rennin-angiotensin system inhibitors (RASIs) in this population have yielded mixed results. We performed a meta-analysis of these trials to evaluate the safety and efficacy of RASIs in heart failure with preserved ejection fraction patients.

Methods: A total of 8425 patients from six prospective randomized controlled trials were analyzed. The end points extracted were total mortality, cardiovascular mortality, hospitalization for heart failure, worsening of heart failure, worsening of renal failure, hyperkalemia, hypotension, six minute walk test, quality of life score. RASIs evaluated were perindopril, enalapril, ramipril, valsartan, candesartan and irbesartan. Combined odds ratios (OR) across all the studies and 95% confidence intervals (CI) were computed. A two-sided alpha error <0.05 was considered to be statistically significant. All studies were homogeneous for outcomes studied, so fixed effect model was used for this meta- analysis.

Results: Both groups share similar baseline characteristics. There was significant reduction in worsening of heart failure events [OR: 1.16, CI: 1.03-1.31; p<0.05] with RASIs compared to placebo group. This was associated with a tendency toward reduced hospitalizations due to heart failure [OR: 1.11, CI: 0.99-1.24; p=0.052] but it could not achieve statistical significance. RASIs also failed to show any benefit in total mortality [OR: 1.07, CI: 0.96-1.19; p=0.19] or cardiovascular mortality [OR: 1.01, CI: 0.89-1.15; p= 0.84] [Figure 1]. However, treatment with RASI lead to significant improvement in six minute walking distance [p<0.05] and quality of life score in RASIs group [p=0.002] [Figure 1]. Safety analysis, as expected, revealed significantly more hyperkalemic events [OR: 0.53, CI: 0.29-0.95; p<0.05] and worsening of renal failure [OR: 0.65, CI: 0.50-0.85; p<0.05] in RASI group as compared to placebo group.

Conclusion: RASIs treatment in heart failure with preserve ejection fraction patients showed significant improvement in six minute walking distance, quality of life and significant reduction in worsening heart failure events but failed to reduce total and cardiovascular mortality.

 

Keywords: ACE inhibitor, Angiotensin receptor blocker, Heart failure with preserved ejection fraction

How to cite this article:

Singh M, Shah T, Adigopula S, Khosla S, Arora R, Jawad E. Safety and efficacy of rennin-angiotensin system inhibitors in heart failure with preserved ejection fraction. International Journal of Collaborative Research on Internal Medicine & Public Health. 2011; 3(4):295-310.

 
Article Options:
Abstract
Full Text (PDF)
Cite this article
Track Citations
Published Online: 10 May 2011
 
Article Sharing Tools:
Email to a friend:  Email
 
 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 

________________________________________________

All rights reserved. 2008-2011
International Online Medical Council (IOMC)
Locations of visitors to this page
Free counter and web stats